![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 15, 2009 7:11:38 AM
Hard To Treat Diseases (HTDS) - CUSIP Change to Force Short Sellers To Cover
* Press Release
* Source: Hard to Treat Diseases
* On Tuesday September 15, 2009, 6:45 am EDT
o
Buzz up! 0
o Print
TORONTO, Sept. 15 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com The issuers received a certain e-mail after the market closed on September 14 2009 where amongst other things Pink Sheets claims that it has received complaints about improper promotions.
The company denies these allegations and finds these allegations disheartening and disingenuous in view of the fact that the issuer is subject to a naked short and has began a vigilant effort to have the shorts cover.
The company believes the short coverings started on September 14 as evidenced by the huge volume and over 100% raise in its share per price values in just a few short hours.
The issuer believes that a huge short position still exists on its security.
The sanctions of Pink Sheets will be namely placing a "Skull and Bones" icon and ranking on HTDS. The issuer will work vigorously to comply with Pink Sheets requests of filing a new Adequate Disclosure which according to Pink Sheets will remove the Skull and Bones rank.
The issuer has completed certain filings with Pink Sheets and an email exchange between both sides can be viewed on this link
http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=24223
HTDS and its advisors cannot and will not allow its security to be systematically erased off the books. Effective today Sept. 15, 2009 HTDS will request a new CUSIP number from its transfer agent. This "time out' which usually lasts 3-4 days to obtain the new CUSIP number will allow the company to prove to Pink Sheets that it had nothing to do with the improper "Promotion", and to complete the filings with Pink Sheets as per the Pink Sheets request see filing TAB or the direct link above.
More importantly, according to the rules, all broker dealers will have to reconcile their accounts and any short positions must be covered. This move by the HTDS management will also preserve the company equity and the last share price as recorded on close of September 14 2009.
During this 3-4 day "time out" the company will provide further updates and news so to assist shareholders with their positions and any short's not covered when the trading resumes. The issuer and its advisers feel that this is the most prudent and best course to take to protect its shareholders and its equity from the short seller's unscrupulous activities. The issuer apologizes for any inconvenience this has caused and assures its shareholders that the short term pain will be well worth the long term gain.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM